Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model
Ann Hematol. 2025 Dec 5. doi: 10.1007/s00277-025-06560-2. Online ahead of print. ABSTRACT Siltuximab is the only approved treatment for idiopathic multicentric Castleman Disease but in …